SCHEMBL14716992

SCHEMBL14716992

[c]1nc2cccc3c2n1CCCC3

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.34
ACHE P22303 5/20 0.33
MAPT P10636 2/20 0.33
HTR2C P28335 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTR2B P41595 1/20 0.33
LIPG Q9Y5X9 2/20 0.32
ALDH1A1 P00352 2/20 0.31
HSD17B10 Q99714 2/20 0.31
MCL1 Q07820 1/20 0.31
USP2 O75604 1/20 0.31
HPGD P15428 1/20 0.31
BCL2L1 Q07817 1/20 0.31
BAD Q92934 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
GFER P55789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7395014 0.95 NPC1 (0.36) TSHRMAPTHTR2CNPC1RAB9A
SCHEMBL14717084 0.88 MEN1 (0.35) MAPTNPC1RAB9ATDP1
SCHEMBL406231 0.68 DRD2 (0.47) TSHRACHEMAPTHTR2CNPC1
SCHEMBL7394360 0.65 HTR2C (0.43) HTR2CHTR2A
SCHEMBL405139 0.62 DRD2 (0.48) MAPTHTR2CNPC1RAB9AALDH1A1
SCHEMBL15828534 0.62 NPC1 (0.37) TSHRMAPTHTR2CNPC1RAB9A
SCHEMBL8548519 0.60 MAPT (0.47) TSHRACHEMAPTNPC1RAB9A
SCHEMBL7424856 0.60 NPC1 (0.50) ACHEMAPTHTR2CNPC1RAB9A
SCHEMBL5057519 0.60 NPC1 (0.50) ACHEMAPTHTR2CNPC1RAB9A
SCHEMBL9078237 0.60 NPC1 (0.56) ACHEMAPTHTR2CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550795-B2 Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds PFIZER INC. (US) 2017-01-24 US disclosed
EP-2751116-B1 HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS PFIZER (US) 2016-10-12 EP disclosed
US-20150087637-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds PFIZER INC. (US) 2015-03-26 US disclosed
US-8933221-B2 Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds PFIZER INC. (US) 2015-01-13 US disclosed
US-20130053373-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds BRODNEY MICHAEL AARON (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053373-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds DPYD, TPMT, QDPR TSHR 327/4885ACHE 375/4885MAPT 1442/4885
US-20150087637-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds DPYD, TPMT, QDPR TSHR 327/4885ACHE 375/4885MAPT 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.